Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
OncoCyte ( (OCX) ) has provided an announcement.
On June 13, 2025, Oncocyte Corporation officially changed its name to Insight Molecular Diagnostics Inc. and relocated its headquarters from Irvine, California, to Nashville, Tennessee. The company’s stock will trade under the new symbol ‘IMDX’ on the Nasdaq Stock Market starting June 18, 2025. This rebranding reflects the company’s expanded strategic direction and diversified product portfolio, including a focus on transplant medicine. iMDx aims to unlock value in the estimated $1 billion market for transplant rejection testing and is committed to delivering a clinically available molecular diagnostic kit for kidney transplant patients. The company is also rebranding its VitaGraft assay under the GraftAssure brand, with new product names GraftAssureCore, GraftAssureIQ, and GraftAssureDx, aligning with regulatory classifications and intended uses.
The most recent analyst rating on (OCX) stock is a Buy with a $4.25 price target. To see the full list of analyst forecasts on OncoCyte stock, see the OCX Stock Forecast page.
Spark’s Take on OCX Stock
According to Spark, TipRanks’ AI Analyst, OCX is a Underperform.
OncoCyte’s overall score is driven by significant financial difficulties, including negative profitability and cash flow challenges. Technical analysis supports a bearish outlook, while valuation concerns stem from negative earnings. Despite some optimism in future guidance, immediate financial and operational hurdles remain paramount.
To see Spark’s full report on OCX stock, click here.
More about OncoCyte
Insight Molecular Diagnostics Inc. (iMDx), formerly known as Oncocyte Corporation, is a pioneering diagnostics technology company focused on democratizing access to novel molecular diagnostic testing to improve patient outcomes. The company specializes in precision biomarker-based testing for transplant and oncology care, with a flagship technology that quantifies donor-derived cell-free DNA (dd-cfDNA) as a biomarker of transplant rejection.
Average Trading Volume: 43,735
Technical Sentiment Signal: Strong Sell
Current Market Cap: $78.08M
Find detailed analytics on OCX stock on TipRanks’ Stock Analysis page.